Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,19740626,dose/concentration ratio (D/C-ratio),"In 10 pregnancies, where samples were available from all three trimesters, the mean TPM dose/concentration ratio (D/C-ratio) was significantly higher than outside pregnancy baseline value 37.3 L/day (+/-15.9), during the 2nd, 67.5L/day (+/-23.4), and the 3rd trimester, 65.1L/day (+/-30.4), but not during the 1st, 49.4 L/day (+/-29.4).",Pharmacokinetics of topiramate during pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740626/),[l] / [d],37.3,4384,DB00273,Topiramate
,19740626,dose/concentration ratio (D/C-ratio),"In 10 pregnancies, where samples were available from all three trimesters, the mean TPM dose/concentration ratio (D/C-ratio) was significantly higher than outside pregnancy baseline value 37.3 L/day (+/-15.9), during the 2nd, 67.5L/day (+/-23.4), and the 3rd trimester, 65.1L/day (+/-30.4), but not during the 1st, 49.4 L/day (+/-29.4).",Pharmacokinetics of topiramate during pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740626/),[l] / [d],67.5,4385,DB00273,Topiramate
,19740626,dose/concentration ratio (D/C-ratio),"In 10 pregnancies, where samples were available from all three trimesters, the mean TPM dose/concentration ratio (D/C-ratio) was significantly higher than outside pregnancy baseline value 37.3 L/day (+/-15.9), during the 2nd, 67.5L/day (+/-23.4), and the 3rd trimester, 65.1L/day (+/-30.4), but not during the 1st, 49.4 L/day (+/-29.4).",Pharmacokinetics of topiramate during pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740626/),[l] / [d],65.1,4386,DB00273,Topiramate
,19740626,dose/concentration ratio (D/C-ratio),"In 10 pregnancies, where samples were available from all three trimesters, the mean TPM dose/concentration ratio (D/C-ratio) was significantly higher than outside pregnancy baseline value 37.3 L/day (+/-15.9), during the 2nd, 67.5L/day (+/-23.4), and the 3rd trimester, 65.1L/day (+/-30.4), but not during the 1st, 49.4 L/day (+/-29.4).",Pharmacokinetics of topiramate during pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740626/),[l] / [d],49.4,4387,DB00273,Topiramate
,19740626,D/C-ratio,"Including seven additional pregnancies enrolled late with data only from the 3rd trimester, the mean D/C-ratio during the 3rd trimester was 67.4 L/day (+/-27.5) compared to baseline, 38.8L/day (+/-18.0), an average increase by 71.8%.",Pharmacokinetics of topiramate during pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740626/),[l] / [d],67.4,4388,DB00273,Topiramate
,19740626,D/C-ratio,"Including seven additional pregnancies enrolled late with data only from the 3rd trimester, the mean D/C-ratio during the 3rd trimester was 67.4 L/day (+/-27.5) compared to baseline, 38.8L/day (+/-18.0), an average increase by 71.8%.",Pharmacokinetics of topiramate during pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740626/),[l] / [d],38.8,4389,DB00273,Topiramate
,16404803,Milk/maternal plasma concentration ratios,"Milk/maternal plasma concentration ratios close to 1 demonstrate extensive transfer to breast milk of many AEDs including ethosuximide, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, topiramate, and zonisamide.",Gender aspects of pharmacokinetics of new and old AEDs: pregnancy and breast-feeding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404803/),,1,16688,DB00273,Topiramate
,23506041,absolute oral bioavailability,The mean (±standard deviation) absolute oral bioavailability was 109% (±10.8%).,Intravenous topiramate: comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23506041/),%,109,22479,DB00273,Topiramate
,23506041,distribution volumes,For intravenous and oral TPM the mean distribution volumes were 1.06 L/kg (±0.29) and 0.94 L/kg (±0.24).,Intravenous topiramate: comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23506041/),[l] / [kg],1.06,22480,DB00273,Topiramate
,23506041,distribution volumes,For intravenous and oral TPM the mean distribution volumes were 1.06 L/kg (±0.29) and 0.94 L/kg (±0.24).,Intravenous topiramate: comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23506041/),[l] / [kg],0.94,22481,DB00273,Topiramate
,23506041,Clearances,Clearances were 1.33 L/h (±0.26) and 1.22 L/h (±0.26).,Intravenous topiramate: comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23506041/),[l] / [h],1.33,22482,DB00273,Topiramate
,23506041,Clearances,Clearances were 1.33 L/h (±0.26) and 1.22 L/h (±0.26).,Intravenous topiramate: comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23506041/),[l] / [h],1.22,22483,DB00273,Topiramate
,23506041,half-life,The half-life values were 42.3 h (±6.2) and 41.2 h (±7.5).,Intravenous topiramate: comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23506041/),h,42.3,22484,DB00273,Topiramate
,23506041,half-life,The half-life values were 42.3 h (±6.2) and 41.2 h (±7.5).,Intravenous topiramate: comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23506041/),h,41.2,22485,DB00273,Topiramate
,11585128,flow-rate,"Liquid chromatographic analysis was carried out on a reversed-phase column (C18, 125x4 mm I.D., 5 microm) using acetonitrile-ammonium acetate buffer, pH 6.3 as the mobile phase, at a flow-rate of 0.8 ml/min.",Simple and rapid liquid chromatographic-turbo ion spray mass spectrometric determination of topiramate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11585128/),[ml] / [min],0.8,24125,DB00273,Topiramate
,11585128,Retention time,Retention time for topiramate was 2.1 min.,Simple and rapid liquid chromatographic-turbo ion spray mass spectrometric determination of topiramate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11585128/),min,2.1,24126,DB00273,Topiramate
,11585128,nebulizer,"Ion source temperature was off; voltage was +5800 V; nebulizer and curtain gas flow-rates were 6 and 10 ml/min, respectively.",Simple and rapid liquid chromatographic-turbo ion spray mass spectrometric determination of topiramate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11585128/),[ml] / [min],6,24127,DB00273,Topiramate
,11585128,nebulizer,"Ion source temperature was off; voltage was +5800 V; nebulizer and curtain gas flow-rates were 6 and 10 ml/min, respectively.",Simple and rapid liquid chromatographic-turbo ion spray mass spectrometric determination of topiramate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11585128/),[ml] / [min],10,24128,DB00273,Topiramate
,11585128,gas flow-rates,"Ion source temperature was off; voltage was +5800 V; nebulizer and curtain gas flow-rates were 6 and 10 ml/min, respectively.",Simple and rapid liquid chromatographic-turbo ion spray mass spectrometric determination of topiramate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11585128/),[ml] / [min],6,24129,DB00273,Topiramate
,11585128,gas flow-rates,"Ion source temperature was off; voltage was +5800 V; nebulizer and curtain gas flow-rates were 6 and 10 ml/min, respectively.",Simple and rapid liquid chromatographic-turbo ion spray mass spectrometric determination of topiramate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11585128/),[ml] / [min],10,24130,DB00273,Topiramate
,11585128,Absolute recovery,Absolute recovery ranged between 92 and 95%.,Simple and rapid liquid chromatographic-turbo ion spray mass spectrometric determination of topiramate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11585128/),%,92 and 95,24131,DB00273,Topiramate
,26943947,Tmax,"Median Tmax was 4h earlier for USL255 sprinkled versus the intact capsule (10 vs 14 h; p=0.0018), and t1/2 was similar (84 vs 82 h, respectively).",Clinical utility of topiramate extended-release capsules (USL255): Bioequivalence of USL255 sprinkled and intact capsule in healthy adults and an in vitro evaluation of sprinkle delivery via enteral feeding tubes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26943947/),h,10,31119,DB00273,Topiramate
,26943947,Tmax,"Median Tmax was 4h earlier for USL255 sprinkled versus the intact capsule (10 vs 14 h; p=0.0018), and t1/2 was similar (84 vs 82 h, respectively).",Clinical utility of topiramate extended-release capsules (USL255): Bioequivalence of USL255 sprinkled and intact capsule in healthy adults and an in vitro evaluation of sprinkle delivery via enteral feeding tubes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26943947/),h,14,31120,DB00273,Topiramate
,26943947,t1/2,"Median Tmax was 4h earlier for USL255 sprinkled versus the intact capsule (10 vs 14 h; p=0.0018), and t1/2 was similar (84 vs 82 h, respectively).",Clinical utility of topiramate extended-release capsules (USL255): Bioequivalence of USL255 sprinkled and intact capsule in healthy adults and an in vitro evaluation of sprinkle delivery via enteral feeding tubes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26943947/),h,84,31121,DB00273,Topiramate
,26943947,t1/2,"Median Tmax was 4h earlier for USL255 sprinkled versus the intact capsule (10 vs 14 h; p=0.0018), and t1/2 was similar (84 vs 82 h, respectively).",Clinical utility of topiramate extended-release capsules (USL255): Bioequivalence of USL255 sprinkled and intact capsule in healthy adults and an in vitro evaluation of sprinkle delivery via enteral feeding tubes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26943947/),h,82,31122,DB00273,Topiramate
,10368080,plasma clearance (CL/F,"In this cohort, mean TPM plasma clearance (CL/F, 66.6+/-27.4 ml/h/kg) was slightly higher than that reported for children and adolescents and therefore substantially higher than that reported for adults.",Topiramate pharmacokinetics in infants. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368080/),[ml] / [h·kg],66.6,36463,DB00273,Topiramate
>,12959634,bioavailability,The bioavailability of the oral formulation of oxcarbazepine is high (>95%).,Clinical pharmacokinetics of oxcarbazepine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),%,95,36869,DB00273,Topiramate
,12959634,plasma protein binding,The plasma protein binding of MHD is about 40%.,Clinical pharmacokinetics of oxcarbazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),%,40,36870,DB00273,Topiramate
,12959634,Elimination half-lives,Elimination half-lives in healthy volunteers are 1-5 hours for oxcarbazepine and 7-20 hours for MHD.,Clinical pharmacokinetics of oxcarbazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),h,1-5,36871,DB00273,Topiramate
,12959634,Elimination half-lives,Elimination half-lives in healthy volunteers are 1-5 hours for oxcarbazepine and 7-20 hours for MHD.,Clinical pharmacokinetics of oxcarbazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),h,7-20,36872,DB00273,Topiramate
>,23841344,m/z,"Negative ions were monitored in the selected reaction monitoring mode (SRM) and transitions m/z 338.2 > 78.2 and m/z 350.3 > 78.2 were used for the quantitative evaluation of TPM and the internal standard, respectively.",Determination of topiramate in human plasma using liquid chromatography tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23841344/),,350.3,38667,DB00273,Topiramate
>,23841344,m/z,"Negative ions were monitored in the selected reaction monitoring mode (SRM) and transitions m/z 338.2 > 78.2 and m/z 350.3 > 78.2 were used for the quantitative evaluation of TPM and the internal standard, respectively.",Determination of topiramate in human plasma using liquid chromatography tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23841344/),,78.2,38668,DB00273,Topiramate
,15509246,apparent oral clearance (CL/F),TPM apparent oral clearance (CL/F) was significantly higher in children taking enzyme-inducing AEDs (85.4 +/- 34.0 ml/h/kg) than in those receiving VPA (49.6 +/- 13.6 ml/h/kg) or neutral AEDs (46.5 +/- 12.8 ml/h/kg).,Topiramate pharmacokinetics in children with epilepsy aged from 6 months to 4 years. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509246/),[ml] / [h·kg],85.4,38692,DB00273,Topiramate
,15509246,apparent oral clearance (CL/F),TPM apparent oral clearance (CL/F) was significantly higher in children taking enzyme-inducing AEDs (85.4 +/- 34.0 ml/h/kg) than in those receiving VPA (49.6 +/- 13.6 ml/h/kg) or neutral AEDs (46.5 +/- 12.8 ml/h/kg).,Topiramate pharmacokinetics in children with epilepsy aged from 6 months to 4 years. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509246/),[ml] / [h·kg],49.6,38693,DB00273,Topiramate
,15509246,apparent oral clearance (CL/F),TPM apparent oral clearance (CL/F) was significantly higher in children taking enzyme-inducing AEDs (85.4 +/- 34.0 ml/h/kg) than in those receiving VPA (49.6 +/- 13.6 ml/h/kg) or neutral AEDs (46.5 +/- 12.8 ml/h/kg).,Topiramate pharmacokinetics in children with epilepsy aged from 6 months to 4 years. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509246/),[ml] / [h·kg],46.5,38694,DB00273,Topiramate
,8930774,Maximum plasma concentrations (Cmax),Maximum plasma concentrations (Cmax) were observed between 1.4 and 4.3 hours after administration.,"Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930774/),,1.4,40270,DB00273,Topiramate
,8930774,oral clearance (Cl/F),Mean oral clearance (Cl/F) was 22.5 to 36.1 mL/min and mean volume of distribution (Vd/F) was 38.5 to 58.0 L.,"Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930774/),[ml] / [min],22.5 to 36.1,40271,DB00273,Topiramate
,8930774,volume of distribution (Vd/F),Mean oral clearance (Cl/F) was 22.5 to 36.1 mL/min and mean volume of distribution (Vd/F) was 38.5 to 58.0 L.,"Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930774/),l,38.5 to 58.0,40272,DB00273,Topiramate
,8930774,Elimination half-life (t1/2),Elimination half-life (t1/2) values calculated from plasma (21.5 hrs) and urinary data (18.5 hrs) were consistent and independent of dose.,"Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930774/),h,21.5,40273,DB00273,Topiramate
,8930774,Elimination half-life (t1/2),Elimination half-life (t1/2) values calculated from plasma (21.5 hrs) and urinary data (18.5 hrs) were consistent and independent of dose.,"Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930774/),h,18.5,40274,DB00273,Topiramate
,8930774,Renal clearance,"Renal clearance was 13.9 mL/min, suggesting that renal tubular reabsorption may be prominently involved in the renal handling of topiramate.","Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930774/),[ml] / [min],13.9,40275,DB00273,Topiramate
,29095797,CD ratio,The mean CD ratio of perampanel was 1740 ± 966 ng·mL·mg·kg in the 17 patients with normal renal function using phenytoin.,Influence of Renal Function on Pharmacokinetics of Antiepileptic Drugs Metabolized by CYP3A4 in a Patient With Renal Impairment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29095797/),kg·mg·ml·ng,1740,43752,DB00273,Topiramate
,29095797,CD ratio,"By contrast, the CD ratio of perampanel was markedly higher (range: 5327-9113 ng·mL·mg·kg) in the patient with renal impairment (CCr: <20 mL/min).",Influence of Renal Function on Pharmacokinetics of Antiepileptic Drugs Metabolized by CYP3A4 in a Patient With Renal Impairment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29095797/),kg·mg·ml·ng,5327-9113,43753,DB00273,Topiramate
,18503564,elimination half-life,"During repeated dosing, steady state is reached within 2 days, consistent with its elimination half-life of 6-10 h.",Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18503564/),h,6-10,45117,DB00273,Topiramate
,9092958,maximal dose,A small TPM monotherapy substitution trial in children with well controlled partial onset seizures showed that TPM monotherapeutic substitution can be achieved successfully with an acceptable amount of adverse experiences with a weekly increase of 1 mg/kg/day to a maximal dose of 3 mg/kg/day.,Preliminary observations on topiramate in pediatric epilepsies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9092958/),[mg] / [d·kg],3,50103,DB00273,Topiramate
,22171585,CL/F,"Eslicarbazepine CL/F was affected by bodyweight, dose of carbamazepine (D(CAR)) and co-administration of barbiturates or phenytoin (AED(PB)), as predicted by the equation CL/F = (2.36 + 0.00149 • D(CAR) + 1.41 • AED(PB)) • (weight/70)0.75, which means that CL/F is 2.36 L/h for a subject with a bodyweight of 70 kg and without concomitant carbamazepine and barbiturates/phenytoin.","Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22171585/),[l] / [h],2.36,53544,DB00273,Topiramate
,15355124,oral clearance,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),[ml] / [min],22-36,55128,DB00273,Topiramate
,15355124,renal clearance,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),[ml] / [min],10-20,55129,DB00273,Topiramate
,15355124,half-life,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),h,19-25,55130,DB00273,Topiramate
,15355124,absolute bioavailability,"The absolute bioavailability, or oral availability, of topiramate is 81-95% and is not affected by food.",Pharmacokinetic interactions of topiramate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),%,81-95,55131,DB00273,Topiramate
,15355124,oral availability,"The absolute bioavailability, or oral availability, of topiramate is 81-95% and is not affected by food.",Pharmacokinetic interactions of topiramate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),%,81-95,55132,DB00273,Topiramate
,14639056,CL/F,"In particular, CL/F values in children aged less than 10 years (112 +/- 82 mL/kg/h, mean +/- SD, n = 14) were almost three times as high as those observed in patients aged >15 to 30 years (42 +/- 16 mL/kg/h, n = 17), whereas the CL/F value in children aged 10 to 15 years (66 +/- 22 mL/kg/h, n = 11) was intermediate between those found in the two other age groups.","Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639056/),[ml] / [h·kg],112,60607,DB00273,Topiramate
,14639056,CL/F,"In particular, CL/F values in children aged less than 10 years (112 +/- 82 mL/kg/h, mean +/- SD, n = 14) were almost three times as high as those observed in patients aged >15 to 30 years (42 +/- 16 mL/kg/h, n = 17), whereas the CL/F value in children aged 10 to 15 years (66 +/- 22 mL/kg/h, n = 11) was intermediate between those found in the two other age groups.","Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639056/),[ml] / [h·kg],42,60608,DB00273,Topiramate
,14639056,CL/F,"In particular, CL/F values in children aged less than 10 years (112 +/- 82 mL/kg/h, mean +/- SD, n = 14) were almost three times as high as those observed in patients aged >15 to 30 years (42 +/- 16 mL/kg/h, n = 17), whereas the CL/F value in children aged 10 to 15 years (66 +/- 22 mL/kg/h, n = 11) was intermediate between those found in the two other age groups.","Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639056/),[ml] / [h·kg],66,60609,DB00273,Topiramate
,23586686,absolute bioavailability,"Pharmacokinetic parameters (mean ± standard deviation [SD]) determined following the intravenous dose included absolute bioavailability: 110 ± 16%, distribution volume: 0.79 ± 0.22 L/kg, clearance: 2.03 ± 1.07 L/h, and elimination half-life: 27.6 ± 9.7 h.",Intravenous topiramate: safety and pharmacokinetics following a single dose in patients with epilepsy or migraines taking oral topiramate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23586686/),%,110,62681,DB00273,Topiramate
,23586686,distribution volume,"Pharmacokinetic parameters (mean ± standard deviation [SD]) determined following the intravenous dose included absolute bioavailability: 110 ± 16%, distribution volume: 0.79 ± 0.22 L/kg, clearance: 2.03 ± 1.07 L/h, and elimination half-life: 27.6 ± 9.7 h.",Intravenous topiramate: safety and pharmacokinetics following a single dose in patients with epilepsy or migraines taking oral topiramate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23586686/),[l] / [kg],0.79,62682,DB00273,Topiramate
,23586686,clearance,"Pharmacokinetic parameters (mean ± standard deviation [SD]) determined following the intravenous dose included absolute bioavailability: 110 ± 16%, distribution volume: 0.79 ± 0.22 L/kg, clearance: 2.03 ± 1.07 L/h, and elimination half-life: 27.6 ± 9.7 h.",Intravenous topiramate: safety and pharmacokinetics following a single dose in patients with epilepsy or migraines taking oral topiramate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23586686/),[l] / [h],2.03,62683,DB00273,Topiramate
,23586686,elimination half-life,"Pharmacokinetic parameters (mean ± standard deviation [SD]) determined following the intravenous dose included absolute bioavailability: 110 ± 16%, distribution volume: 0.79 ± 0.22 L/kg, clearance: 2.03 ± 1.07 L/h, and elimination half-life: 27.6 ± 9.7 h.",Intravenous topiramate: safety and pharmacokinetics following a single dose in patients with epilepsy or migraines taking oral topiramate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23586686/),h,27.6,62684,DB00273,Topiramate
,24725807,clearance,Hemodialysis effectively removed plasma topiramate with mean dialysis clearance approximately 12-fold greater than CL/F (123.5 mL/min versus 10.8 mL/min).,"Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24725807/),[ml] / [min],123.5,62810,DB00273,Topiramate
,24725807,CL/F,Hemodialysis effectively removed plasma topiramate with mean dialysis clearance approximately 12-fold greater than CL/F (123.5 mL/min versus 10.8 mL/min).,"Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24725807/),[ml] / [min],123.5,62811,DB00273,Topiramate
,24725807,CL/F,Hemodialysis effectively removed plasma topiramate with mean dialysis clearance approximately 12-fold greater than CL/F (123.5 mL/min versus 10.8 mL/min).,"Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24725807/),[ml] / [min],10.8,62812,DB00273,Topiramate
,31222537,apparent clearance (CL/F),"Average parameter estimates for valproic acid apparent clearance (CL/F) and apparent volume of distribution (V/F) were 0.14 L/h and 37.7 L (fixed), respectively.",Estimation of apparent clearance of valproic acid in adult Saudi patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31222537/),[l] / [h],0.14,63153,DB00273,Topiramate
,31222537,apparent volume of distribution (V/F),"Average parameter estimates for valproic acid apparent clearance (CL/F) and apparent volume of distribution (V/F) were 0.14 L/h and 37.7 L (fixed), respectively.",Estimation of apparent clearance of valproic acid in adult Saudi patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31222537/),l,37.7,63154,DB00273,Topiramate
,12823574,AUCss,"The exposure, or area under the plasma LTG concentration-time curve within a dosing interval at steady state (AUCss), did not change in the presence of TPM, with mean AUCss values ranging at each TPM dose level between 66 and 81 mg x h/L with concomitant LTG/TPM therapy compared with 77 mgxh/L with LTG monotherapy.",Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12823574/),[h·mg] / [l],66 and 81,65036,DB00273,Topiramate
,12823574,AUCss,"The exposure, or area under the plasma LTG concentration-time curve within a dosing interval at steady state (AUCss), did not change in the presence of TPM, with mean AUCss values ranging at each TPM dose level between 66 and 81 mg x h/L with concomitant LTG/TPM therapy compared with 77 mgxh/L with LTG monotherapy.",Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12823574/),[h·mg] / [l],77,65037,DB00273,Topiramate
,12823574,oral clearance (CL/F),The mean (+/-SD) oral clearance (CL/F) of TPM (400 mg/day) was 2.6 +/- 1.1 L/h when given alone and 2.7 +/- 0.7 L/h when given with LTG.,Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12823574/),[l] / [h],2.6,65038,DB00273,Topiramate
,12823574,oral clearance (CL/F),The mean (+/-SD) oral clearance (CL/F) of TPM (400 mg/day) was 2.6 +/- 1.1 L/h when given alone and 2.7 +/- 0.7 L/h when given with LTG.,Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12823574/),[l] / [h],2.7,65039,DB00273,Topiramate
,32502686,globule size,Topiramate loaded nanoemulsion was having a globule size of 4.73 ± 0.52 nm.,"Intranasal delivery of topiramate nanoemulsion: Pharmacodynamic, pharmacokinetic and brain uptake studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32502686/),nm,4.73,65087,DB00273,Topiramate
,10704102,retention times,"A DB-5, fused silica capillary column (J&W Scientific, Folsom, CA) was used, yielding typical retention times of 4.95 min for topiramate and 5.32 min for the internal standard in human plasma.","A capillary gas chromatographic assay with nitrogen phosphorus detection for the quantification of topiramate in human plasma, urine and whole blood. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10704102/),min,4.95,69475,DB00273,Topiramate
,10704102,retention times,"A DB-5, fused silica capillary column (J&W Scientific, Folsom, CA) was used, yielding typical retention times of 4.95 min for topiramate and 5.32 min for the internal standard in human plasma.","A capillary gas chromatographic assay with nitrogen phosphorus detection for the quantification of topiramate in human plasma, urine and whole blood. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10704102/),min,5.32,69476,DB00273,Topiramate
,19593736,m/,Turbo-spray negative-ion mode multiple-reaction monitoring was selected for mass pair detection at m/z 338.3 --> 78.0 and m/z 407.3 --> 295.5 for analyte and IS respectively.,Bioanalytical LC-MS/MS method validation for plasma determination of topiramate in healthy Indian volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19593736/),,338.3,71595,DB00273,Topiramate
,19593736,m/,Turbo-spray negative-ion mode multiple-reaction monitoring was selected for mass pair detection at m/z 338.3 --> 78.0 and m/z 407.3 --> 295.5 for analyte and IS respectively.,Bioanalytical LC-MS/MS method validation for plasma determination of topiramate in healthy Indian volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19593736/),,78.0,71596,DB00273,Topiramate
,19593736,m/z,Turbo-spray negative-ion mode multiple-reaction monitoring was selected for mass pair detection at m/z 338.3 --> 78.0 and m/z 407.3 --> 295.5 for analyte and IS respectively.,Bioanalytical LC-MS/MS method validation for plasma determination of topiramate in healthy Indian volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19593736/),,407.3,71597,DB00273,Topiramate
,19593736,m/z,Turbo-spray negative-ion mode multiple-reaction monitoring was selected for mass pair detection at m/z 338.3 --> 78.0 and m/z 407.3 --> 295.5 for analyte and IS respectively.,Bioanalytical LC-MS/MS method validation for plasma determination of topiramate in healthy Indian volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19593736/),,295.5,71598,DB00273,Topiramate
within,19593736,total run time,"The method showed a dynamic linearity range from 10.4 to 2045.0 ng/mL, lower limit of quantitation achieved at 10.4 ng/mL and finally a mass spectrometric total run time of within 2.5 min for human sample analysis.",Bioanalytical LC-MS/MS method validation for plasma determination of topiramate in healthy Indian volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19593736/),min,2.5,71599,DB00273,Topiramate
,19593736,half-life matching,"The challenge of half-life matching for test and reference drug was achieved with 73.43 +/- 9.68 and 73.06 +/- 14.03 h, respectively, and intra-subject coefficient of variation achieved within 11% for AUCs and C(max) evaluated by non-compartmental pharmacokinetic analysis.",Bioanalytical LC-MS/MS method validation for plasma determination of topiramate in healthy Indian volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19593736/),h,73.43,71600,DB00273,Topiramate
,19593736,half-life matching,"The challenge of half-life matching for test and reference drug was achieved with 73.43 +/- 9.68 and 73.06 +/- 14.03 h, respectively, and intra-subject coefficient of variation achieved within 11% for AUCs and C(max) evaluated by non-compartmental pharmacokinetic analysis.",Bioanalytical LC-MS/MS method validation for plasma determination of topiramate in healthy Indian volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19593736/),h,73.06,71601,DB00273,Topiramate
,21770925,relative bioavailability (F),"USL255 fasted pharmacokinetic parameters [point estimate (90% confidence interval, CI) compared to Topamax] were: relative bioavailability (F) 91.2% (84-99%), peak plasma concentration (C(max)) USL255/Topamax-ratio 59% (53-65%), time to reach C(max) (t(max)) 19.5 ± 7.2 h, accumulation ratio (R(ac)) 3.9 ± 1.2, effective half-life (t(1/2,eff)) 55.7 ± 19.9 h, terminal half-life (t(1/2,z)) 80.2 ± 14.2 h, and peak-occupancy-time (POT) 12.1 ± 4.0 h.","Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21770925/),%,91.2,71739,DB00273,Topiramate
,21770925,ratio,"USL255 fasted pharmacokinetic parameters [point estimate (90% confidence interval, CI) compared to Topamax] were: relative bioavailability (F) 91.2% (84-99%), peak plasma concentration (C(max)) USL255/Topamax-ratio 59% (53-65%), time to reach C(max) (t(max)) 19.5 ± 7.2 h, accumulation ratio (R(ac)) 3.9 ± 1.2, effective half-life (t(1/2,eff)) 55.7 ± 19.9 h, terminal half-life (t(1/2,z)) 80.2 ± 14.2 h, and peak-occupancy-time (POT) 12.1 ± 4.0 h.","Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21770925/),%,59,71740,DB00273,Topiramate
,21770925,time to reach C(max) (t(max)),"USL255 fasted pharmacokinetic parameters [point estimate (90% confidence interval, CI) compared to Topamax] were: relative bioavailability (F) 91.2% (84-99%), peak plasma concentration (C(max)) USL255/Topamax-ratio 59% (53-65%), time to reach C(max) (t(max)) 19.5 ± 7.2 h, accumulation ratio (R(ac)) 3.9 ± 1.2, effective half-life (t(1/2,eff)) 55.7 ± 19.9 h, terminal half-life (t(1/2,z)) 80.2 ± 14.2 h, and peak-occupancy-time (POT) 12.1 ± 4.0 h.","Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21770925/),h,19.5,71741,DB00273,Topiramate
,21770925,accumulation ratio (R(ac)),"USL255 fasted pharmacokinetic parameters [point estimate (90% confidence interval, CI) compared to Topamax] were: relative bioavailability (F) 91.2% (84-99%), peak plasma concentration (C(max)) USL255/Topamax-ratio 59% (53-65%), time to reach C(max) (t(max)) 19.5 ± 7.2 h, accumulation ratio (R(ac)) 3.9 ± 1.2, effective half-life (t(1/2,eff)) 55.7 ± 19.9 h, terminal half-life (t(1/2,z)) 80.2 ± 14.2 h, and peak-occupancy-time (POT) 12.1 ± 4.0 h.","Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21770925/),,3.9,71742,DB00273,Topiramate
,21770925,"effective half-life (t(1/2,eff))","USL255 fasted pharmacokinetic parameters [point estimate (90% confidence interval, CI) compared to Topamax] were: relative bioavailability (F) 91.2% (84-99%), peak plasma concentration (C(max)) USL255/Topamax-ratio 59% (53-65%), time to reach C(max) (t(max)) 19.5 ± 7.2 h, accumulation ratio (R(ac)) 3.9 ± 1.2, effective half-life (t(1/2,eff)) 55.7 ± 19.9 h, terminal half-life (t(1/2,z)) 80.2 ± 14.2 h, and peak-occupancy-time (POT) 12.1 ± 4.0 h.","Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21770925/),h,55.7,71743,DB00273,Topiramate
,21770925,"terminal half-life (t(1/2,z))","USL255 fasted pharmacokinetic parameters [point estimate (90% confidence interval, CI) compared to Topamax] were: relative bioavailability (F) 91.2% (84-99%), peak plasma concentration (C(max)) USL255/Topamax-ratio 59% (53-65%), time to reach C(max) (t(max)) 19.5 ± 7.2 h, accumulation ratio (R(ac)) 3.9 ± 1.2, effective half-life (t(1/2,eff)) 55.7 ± 19.9 h, terminal half-life (t(1/2,z)) 80.2 ± 14.2 h, and peak-occupancy-time (POT) 12.1 ± 4.0 h.","Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21770925/),h,80.2,71744,DB00273,Topiramate
,21770925,peak-occupancy-time (POT),"USL255 fasted pharmacokinetic parameters [point estimate (90% confidence interval, CI) compared to Topamax] were: relative bioavailability (F) 91.2% (84-99%), peak plasma concentration (C(max)) USL255/Topamax-ratio 59% (53-65%), time to reach C(max) (t(max)) 19.5 ± 7.2 h, accumulation ratio (R(ac)) 3.9 ± 1.2, effective half-life (t(1/2,eff)) 55.7 ± 19.9 h, terminal half-life (t(1/2,z)) 80.2 ± 14.2 h, and peak-occupancy-time (POT) 12.1 ± 4.0 h.","Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21770925/),h,12.1,71745,DB00273,Topiramate
,21770925,F,"Although the F and C(max) were unaffected by food, R(ac) and t(1/2,eff) increased to 4.9 ± 0.9, and 72.5 ± 15.4 h, respectively.","Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21770925/),h,4.9,71746,DB00273,Topiramate
,21770925,R(ac),"Although the F and C(max) were unaffected by food, R(ac) and t(1/2,eff) increased to 4.9 ± 0.9, and 72.5 ± 15.4 h, respectively.","Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21770925/),h,4.9,71747,DB00273,Topiramate
,21770925,"t(1/2,eff)","Although the F and C(max) were unaffected by food, R(ac) and t(1/2,eff) increased to 4.9 ± 0.9, and 72.5 ± 15.4 h, respectively.","Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21770925/),h,72.5,71748,DB00273,Topiramate
,21770925,"t(1/2,eff)","In contrast to t(1/2,z,) t(1/2,eff) reflects absorption rate; therefore, USL255's t(1/2,eff) was significantly longer than Topamax's t(1/2,eff) (37.1 ± 6.5 h).","Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21770925/),h,37.1,71749,DB00273,Topiramate
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],2.52,74496,DB00273,Topiramate
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],2.17,74497,DB00273,Topiramate
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],1.803,74498,DB00273,Topiramate
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],1.636,74499,DB00273,Topiramate
,15828853,CL/F,"In the absence of enzyme-inducing comedication, mean topiramate CL/F was 42% higher in children than in adults (40.3 +/- 21.0 vs 28.4 +/- 15.3 mL/h/kg; p < 0.01).",Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15828853/),[ml] / [h·kg],40.3,77338,DB00273,Topiramate
,15828853,CL/F,"In the absence of enzyme-inducing comedication, mean topiramate CL/F was 42% higher in children than in adults (40.3 +/- 21.0 vs 28.4 +/- 15.3 mL/h/kg; p < 0.01).",Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15828853/),[ml] / [h·kg],28.4,77339,DB00273,Topiramate
,15828853,CL/F,"In children and adults comedicated with enzyme-inducing antiepileptic drugs (AEDs), topiramate CL/F values were approximately 1.5- to 2-fold higher than those observed in the absence of enzyme inducers, and the elevation in topiramate CL/F in children compared with adults was also present in the subgroups receiving enzyme inducers (66%; 76.6 +/- 35.1 vs 46.1 +/- 16.7 mL/h/kg; p < 0.0001).",Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15828853/),[ml] / [h·kg],76.6,77340,DB00273,Topiramate
,15828853,CL/F,"In children and adults comedicated with enzyme-inducing antiepileptic drugs (AEDs), topiramate CL/F values were approximately 1.5- to 2-fold higher than those observed in the absence of enzyme inducers, and the elevation in topiramate CL/F in children compared with adults was also present in the subgroups receiving enzyme inducers (66%; 76.6 +/- 35.1 vs 46.1 +/- 16.7 mL/h/kg; p < 0.0001).",Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15828853/),[ml] / [h·kg],46.1,77341,DB00273,Topiramate
,20606310,Volume of distribution,Volume of distribution of topiramate was 0.518 l/kg.,A nonlinear mixed effects modelling analysis of topiramate pharmacokinetics in patients with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20606310/),[l] / [kg],0.518,78908,DB00273,Topiramate
,20606310,oral clearance,"For a typical patient oral clearance was estimated at 1.47 l/h, with interindividual variability of 39.2%.",A nonlinear mixed effects modelling analysis of topiramate pharmacokinetics in patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20606310/),[l] / [h],1.47,78909,DB00273,Topiramate
,25220641,Ka,"The population values of pharmacokinetic parameters estimated in the final model were as follows: Ka=0.83 h-1, Vd=0.67 L/kg, and CL=0.035 L·kg(-1)·h(-1).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),1/[h],0.83,82170,DB00273,Topiramate
,25220641,Vd,"The population values of pharmacokinetic parameters estimated in the final model were as follows: Ka=0.83 h-1, Vd=0.67 L/kg, and CL=0.035 L·kg(-1)·h(-1).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[l] / [kg],0.67,82171,DB00273,Topiramate
,25220641,CL,"The population values of pharmacokinetic parameters estimated in the final model were as follows: Ka=0.83 h-1, Vd=0.67 L/kg, and CL=0.035 L·kg(-1)·h(-1).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[l] / [h·kg],0.035,82172,DB00273,Topiramate
,25220641,MP,"For the final model, the evaluation results (95% CI) were MPE=0.01 (-0.07-0.10) mg/L, MAE=0.46 (0.40-0.51) mg/L, MSE=0.39 (0.27-0.51) (mg/L)(2).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[mg] / [l],0.01,82173,DB00273,Topiramate
,25220641,MAE,"For the final model, the evaluation results (95% CI) were MPE=0.01 (-0.07-0.10) mg/L, MAE=0.46 (0.40-0.51) mg/L, MSE=0.39 (0.27-0.51) (mg/L)(2).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[mg] / [l],0.46,82174,DB00273,Topiramate
,25220641,MSE,"For the final model, the evaluation results (95% CI) were MPE=0.01 (-0.07-0.10) mg/L, MAE=0.46 (0.40-0.51) mg/L, MSE=0.39 (0.27-0.51) (mg/L)(2).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),,0.39,82175,DB00273,Topiramate
>,15301575,bioavailability,"After oral ingestion, levetiracetam is rapidly absorbed, with peak concentration occurring after 1.3 hours, and its bioavailability is >95%.",Clinical pharmacokinetics of levetiracetam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301575/),%,95,93302,DB00273,Topiramate
,15301575,volume of distribution,Levetiracetam is not bound to plasma proteins and has a volume of distribution of 0.5-0.7 L/kg.,Clinical pharmacokinetics of levetiracetam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301575/),[l] / [kg],0.5-0.7,93303,DB00273,Topiramate
,15301575,elimination half-life,"The elimination half-life in adult volunteers, adults with epilepsy, children with epilepsy and elderly volunteers is 6-8, 6-8, 5-7 and 10-11 hours, respectively.",Clinical pharmacokinetics of levetiracetam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301575/),h,6-8,93304,DB00273,Topiramate
,15301575,elimination half-life,"The elimination half-life in adult volunteers, adults with epilepsy, children with epilepsy and elderly volunteers is 6-8, 6-8, 5-7 and 10-11 hours, respectively.",Clinical pharmacokinetics of levetiracetam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301575/),h,5-7,93305,DB00273,Topiramate
,15301575,elimination half-life,"The elimination half-life in adult volunteers, adults with epilepsy, children with epilepsy and elderly volunteers is 6-8, 6-8, 5-7 and 10-11 hours, respectively.",Clinical pharmacokinetics of levetiracetam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15301575/),h,10-11,93306,DB00273,Topiramate
over,10612356,elimination half-lives,"The route of elimination differs to an important extent from one compound to another, and elimination half-lives range from over 30 h for zonisamide to 5-7 h for gabapentin.",The clinical pharmacokinetics of the new antiepileptic drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10612356/),h,30,106800,DB00273,Topiramate
,10612356,elimination half-lives,"The route of elimination differs to an important extent from one compound to another, and elimination half-lives range from over 30 h for zonisamide to 5-7 h for gabapentin.",The clinical pharmacokinetics of the new antiepileptic drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10612356/),h,5-7,106801,DB00273,Topiramate
,12973408,volume of distribution,"The volume of distribution is 0.6-0.8 l/kg, suggesting distribution into total body water.",Pharmacokinetics and metabolism of topiramate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12973408/),[l] / [kg],0.6-0.8,108482,DB00273,Topiramate
,27883934,t1/2z,"As previously reported, mean t1/2z was similar between USL255 (80.2h) and TPM-IR (82.8h); TPM-IR t1/2z was ∼4 times longer than reported in the Topamax label (21h).",The application of half-life in clinical decision making: Comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27883934/),h,80.2,116524,DB00273,Topiramate
,27883934,t1/2z,"As previously reported, mean t1/2z was similar between USL255 (80.2h) and TPM-IR (82.8h); TPM-IR t1/2z was ∼4 times longer than reported in the Topamax label (21h).",The application of half-life in clinical decision making: Comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27883934/),h,82.8,116525,DB00273,Topiramate
,27883934,t1/2z,"As previously reported, mean t1/2z was similar between USL255 (80.2h) and TPM-IR (82.8h); TPM-IR t1/2z was ∼4 times longer than reported in the Topamax label (21h).",The application of half-life in clinical decision making: Comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27883934/),h,21,116526,DB00273,Topiramate
,27883934,t1/2eff,"In contrast, USL255 displayed a 1.5 fold longer t1/2eff (55.7 vs 37.1h for TPM-IR).",The application of half-life in clinical decision making: Comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27883934/),h,55.7,116527,DB00273,Topiramate
,27883934,t1/2eff,"In contrast, USL255 displayed a 1.5 fold longer t1/2eff (55.7 vs 37.1h for TPM-IR).",The application of half-life in clinical decision making: Comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27883934/),h,37.1,116528,DB00273,Topiramate
,27883934,t1/2z,"When t1/2z was calculated from 48 to 336h, values ranged from 28.8 to 82.8h.",The application of half-life in clinical decision making: Comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27883934/),h,48 to 336,116529,DB00273,Topiramate
,27883934,t1/2z,"When t1/2z was calculated from 48 to 336h, values ranged from 28.8 to 82.8h.",The application of half-life in clinical decision making: Comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27883934/),h,28.8 to 82.8,116530,DB00273,Topiramate
,23891703,Volume of distribution,Volume of distribution of TPM was estimated at 0.575 l/kg.,Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23891703/),[l] / [kg],0.575,116785,DB00273,Topiramate
,23891703,CL/F,"Mean TPM CL/F during CBZ co-therapy was 2.46 l/h, which is higher for 60.8% than in patients not co-treated with CBZ.",Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23891703/),[l] / [h],2.46,116786,DB00273,Topiramate
,12366729,milk/maternal plasma concentration ratio,"The mean milk/maternal plasma concentration ratio was 0.86 (range, 0.67-1.1) at 2-3 weeks after delivery.","Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12366729/),,0.86,117514,DB00273,Topiramate
,12366729,milk/maternal plasma concentration ratios,"The milk/maternal plasma concentration ratios at sampling 1 and 3 months after delivery were similar (0.86 and 0.69, respectively).","Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12366729/),,0.86,117515,DB00273,Topiramate
,12366729,milk/maternal plasma concentration ratios,"The milk/maternal plasma concentration ratios at sampling 1 and 3 months after delivery were similar (0.86 and 0.69, respectively).","Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12366729/),,0.69,117516,DB00273,Topiramate
,10371378,CL/F,Weight-normalized topiramate CL/F was higher (P = 0.003) in pediatric patients receiving enzyme-inducing concomitant antiepileptic drugs (AEDs) (mean = 70.1 ml/minute/70 kg) than in those not receiving enzyme-inducing AEDs (mean = 33.1 mL/ minute/kg).,A study of topiramate pharmacokinetics and tolerability in children with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10371378/),[ml] / [70·kg·min],70.1,129292,DB00273,Topiramate
,10371378,CL/F,Weight-normalized topiramate CL/F was higher (P = 0.003) in pediatric patients receiving enzyme-inducing concomitant antiepileptic drugs (AEDs) (mean = 70.1 ml/minute/70 kg) than in those not receiving enzyme-inducing AEDs (mean = 33.1 mL/ minute/kg).,A study of topiramate pharmacokinetics and tolerability in children with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10371378/),[ml] / [kg·min],33.1,129293,DB00273,Topiramate
,25403343,time to maximal concentration,"Topiramate was rapidly absorbed, with a median time to maximal concentration of 1 h and an oral bioavailability of ~100%.",Pharmacokinetic-pharmacodynamic modelling of intravenous and oral topiramate and its effect on phonemic fluency in adult healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25403343/),h,1,134071,DB00273,Topiramate
,25403343,oral bioavailability,"Topiramate was rapidly absorbed, with a median time to maximal concentration of 1 h and an oral bioavailability of ~100%.",Pharmacokinetic-pharmacodynamic modelling of intravenous and oral topiramate and its effect on phonemic fluency in adult healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25403343/),%,100,134072,DB00273,Topiramate
,21166024,flow rate,Topiramate and the topiramate d-12 internal standard (IS) were chromatographed on a Betasil C18 column at a flow rate of 0.5 mL/min.,"A simple, rapid and specific method for measurement of topiramate in human plasma by LC-MS/MS employing automated solid-phase extraction techniques: Application for bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166024/),[ml] / [min],0.5,145469,DB00273,Topiramate
,21166024,total run time,The total run time was 1.80 min.,"A simple, rapid and specific method for measurement of topiramate in human plasma by LC-MS/MS employing automated solid-phase extraction techniques: Application for bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166024/),min,1.80,145470,DB00273,Topiramate
,21166024,mass,"The mass transition [M-H] ions used for detection were m/z 338.10→78.20 for topiramate, m/z 350.40→90.10 for IS.","A simple, rapid and specific method for measurement of topiramate in human plasma by LC-MS/MS employing automated solid-phase extraction techniques: Application for bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166024/),,338.10,145471,DB00273,Topiramate
,21166024,m/z,"The mass transition [M-H] ions used for detection were m/z 338.10→78.20 for topiramate, m/z 350.40→90.10 for IS.","A simple, rapid and specific method for measurement of topiramate in human plasma by LC-MS/MS employing automated solid-phase extraction techniques: Application for bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166024/),,338.10,145472,DB00273,Topiramate
,21166024,m/z,"The mass transition [M-H] ions used for detection were m/z 338.10→78.20 for topiramate, m/z 350.40→90.10 for IS.","A simple, rapid and specific method for measurement of topiramate in human plasma by LC-MS/MS employing automated solid-phase extraction techniques: Application for bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166024/),,78.20,145473,DB00273,Topiramate
,21166024,m/z,"The mass transition [M-H] ions used for detection were m/z 338.10→78.20 for topiramate, m/z 350.40→90.10 for IS.","A simple, rapid and specific method for measurement of topiramate in human plasma by LC-MS/MS employing automated solid-phase extraction techniques: Application for bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166024/),,350.40,145474,DB00273,Topiramate
,21166024,m/z,"The mass transition [M-H] ions used for detection were m/z 338.10→78.20 for topiramate, m/z 350.40→90.10 for IS.","A simple, rapid and specific method for measurement of topiramate in human plasma by LC-MS/MS employing automated solid-phase extraction techniques: Application for bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166024/),,90.10,145475,DB00273,Topiramate
,21166024,Recovery,Recovery of topiramate and IS ranged from 78.20 to 87.74%.,"A simple, rapid and specific method for measurement of topiramate in human plasma by LC-MS/MS employing automated solid-phase extraction techniques: Application for bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166024/),%,78.20 to 87.74,145476,DB00273,Topiramate
,9070595,oral,TPM oral and renal clearances (n = 8) were 25.9 +/- 4.6 and 11.6 +/- 3.2 ml/min during TPM monotherapy and were 29.8 +/- 4.2 and 12.4 +/- 2.7 ml/min during VPA concomitant therapy.,Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9070595/),[ml] / [min],25.9,149558,DB00273,Topiramate
,9070595,oral,TPM oral and renal clearances (n = 8) were 25.9 +/- 4.6 and 11.6 +/- 3.2 ml/min during TPM monotherapy and were 29.8 +/- 4.2 and 12.4 +/- 2.7 ml/min during VPA concomitant therapy.,Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9070595/),[ml] / [min],29.8,149559,DB00273,Topiramate
,9070595,renal clearances,TPM oral and renal clearances (n = 8) were 25.9 +/- 4.6 and 11.6 +/- 3.2 ml/min during TPM monotherapy and were 29.8 +/- 4.2 and 12.4 +/- 2.7 ml/min during VPA concomitant therapy.,Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9070595/),[ml] / [min],11.6,149560,DB00273,Topiramate
,9070595,renal clearances,TPM oral and renal clearances (n = 8) were 25.9 +/- 4.6 and 11.6 +/- 3.2 ml/min during TPM monotherapy and were 29.8 +/- 4.2 and 12.4 +/- 2.7 ml/min during VPA concomitant therapy.,Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9070595/),[ml] / [min],12.4,149561,DB00273,Topiramate
,9070595,oral clearance,"VPA oral clearance was 12.8 +/- 4.1 ml/min during monotherapy and was 13.8 +/- 4.0, 14.1 +/- 3.9, and 14.5 +/- 5.2 ml/min during coadministration of TPM 100, 200, and 400 mg every 12 h, respectively.",Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9070595/),[ml] / [min],12.8,149562,DB00273,Topiramate
,9070595,oral clearance,"VPA oral clearance was 12.8 +/- 4.1 ml/min during monotherapy and was 13.8 +/- 4.0, 14.1 +/- 3.9, and 14.5 +/- 5.2 ml/min during coadministration of TPM 100, 200, and 400 mg every 12 h, respectively.",Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9070595/),[ml] / [min],13.8,149563,DB00273,Topiramate
,9070595,oral clearance,"VPA oral clearance was 12.8 +/- 4.1 ml/min during monotherapy and was 13.8 +/- 4.0, 14.1 +/- 3.9, and 14.5 +/- 5.2 ml/min during coadministration of TPM 100, 200, and 400 mg every 12 h, respectively.",Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9070595/),[ml] / [min],14.1,149564,DB00273,Topiramate
,9070595,oral clearance,"VPA oral clearance was 12.8 +/- 4.1 ml/min during monotherapy and was 13.8 +/- 4.0, 14.1 +/- 3.9, and 14.5 +/- 5.2 ml/min during coadministration of TPM 100, 200, and 400 mg every 12 h, respectively.",Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9070595/),[ml] / [min],14.5,149565,DB00273,Topiramate
,12102670,area under the curve (AUC) ratio,"In nine of the 12 patients, PHT plasma concentrations remained stable, with a mean (+/-SD) area under the curve (AUC) ratio (combination therapy/monotherapy) of 1.13 +/- 0.17 (range, 0.89-1.23).",Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12102670/),,1.13,155947,DB00273,Topiramate
,12102670,AUC ratios,"Three patients had AUC ratios of 1.25, 1.39, and 1.55, respectively, and with the addition of TPM (800, 400, and 400 mg daily, respectively), their peak PHT plasma concentrations increased from 15 to 21 mg/L, 28 to 36 mg/L, and 27 to 41 mg/L, respectively.",Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12102670/),,1.25,155948,DB00273,Topiramate
,12102670,AUC ratios,"Three patients had AUC ratios of 1.25, 1.39, and 1.55, respectively, and with the addition of TPM (800, 400, and 400 mg daily, respectively), their peak PHT plasma concentrations increased from 15 to 21 mg/L, 28 to 36 mg/L, and 27 to 41 mg/L, respectively.",Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12102670/),,1.39,155949,DB00273,Topiramate
,12102670,AUC ratios,"Three patients had AUC ratios of 1.25, 1.39, and 1.55, respectively, and with the addition of TPM (800, 400, and 400 mg daily, respectively), their peak PHT plasma concentrations increased from 15 to 21 mg/L, 28 to 36 mg/L, and 27 to 41 mg/L, respectively.",Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12102670/),,1.55,155950,DB00273,Topiramate
,12102670,peak PHT plasma concentrations,"Three patients had AUC ratios of 1.25, 1.39, and 1.55, respectively, and with the addition of TPM (800, 400, and 400 mg daily, respectively), their peak PHT plasma concentrations increased from 15 to 21 mg/L, 28 to 36 mg/L, and 27 to 41 mg/L, respectively.",Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12102670/),[mg] / [l],15 to 21,155951,DB00273,Topiramate
,12102670,peak PHT plasma concentrations,"Three patients had AUC ratios of 1.25, 1.39, and 1.55, respectively, and with the addition of TPM (800, 400, and 400 mg daily, respectively), their peak PHT plasma concentrations increased from 15 to 21 mg/L, 28 to 36 mg/L, and 27 to 41 mg/L, respectively.",Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12102670/),[mg] / [l],28 to 36,155952,DB00273,Topiramate
,12102670,peak PHT plasma concentrations,"Three patients had AUC ratios of 1.25, 1.39, and 1.55, respectively, and with the addition of TPM (800, 400, and 400 mg daily, respectively), their peak PHT plasma concentrations increased from 15 to 21 mg/L, 28 to 36 mg/L, and 27 to 41 mg/L, respectively.",Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12102670/),[mg] / [l],27 to 41,155953,DB00273,Topiramate
,20377319,elimination half-life,"However, there was no difference between TPM elimination half-life following TPM co-administered with ESL and TPM administered alone (24.0 and 24.3 h, respectively).",Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20377319/),h,24.0,162307,DB00273,Topiramate
,20377319,elimination half-life,"However, there was no difference between TPM elimination half-life following TPM co-administered with ESL and TPM administered alone (24.0 and 24.3 h, respectively).",Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20377319/),h,24.3,162308,DB00273,Topiramate
,18348335,m/z,"The ionization was optimized using ESI(-) and selectivity was achieved by MS/MS analysis, m/z 338.0 --> 77.5 and m/z 357.1 --> 327.2 for topiramate and prednisone, respectively.",Determination of plasma topiramate concentration using LC-MS/MS for pharmacokinetic and bioequivalence studies in healthy Korean volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18348335/),,338.0,176998,DB00273,Topiramate
,18348335,m/z,"The ionization was optimized using ESI(-) and selectivity was achieved by MS/MS analysis, m/z 338.0 --> 77.5 and m/z 357.1 --> 327.2 for topiramate and prednisone, respectively.",Determination of plasma topiramate concentration using LC-MS/MS for pharmacokinetic and bioequivalence studies in healthy Korean volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18348335/),,77.5,176999,DB00273,Topiramate
,18348335,m/z,"The ionization was optimized using ESI(-) and selectivity was achieved by MS/MS analysis, m/z 338.0 --> 77.5 and m/z 357.1 --> 327.2 for topiramate and prednisone, respectively.",Determination of plasma topiramate concentration using LC-MS/MS for pharmacokinetic and bioequivalence studies in healthy Korean volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18348335/),,357.1,177000,DB00273,Topiramate
,18348335,m/z,"The ionization was optimized using ESI(-) and selectivity was achieved by MS/MS analysis, m/z 338.0 --> 77.5 and m/z 357.1 --> 327.2 for topiramate and prednisone, respectively.",Determination of plasma topiramate concentration using LC-MS/MS for pharmacokinetic and bioequivalence studies in healthy Korean volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18348335/),,327.2,177001,DB00273,Topiramate
,18348335,total run time,The method had a total run time of 2.5 min and showed good linearity over a working range of 20-5000 ng/mL in human plasma with a lower limit of quantification of 20 ng/mL.,Determination of plasma topiramate concentration using LC-MS/MS for pharmacokinetic and bioequivalence studies in healthy Korean volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18348335/),min,2.5,177002,DB00273,Topiramate
,20376593,Peak serum topiramate level,"Peak serum topiramate level was 356.6 microg/ml (reference range, 5-20 microg/ml).",Clinical effects and toxicokinetic evaluation following massive topiramate ingestion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20376593/),[μg] / [ml],356.6,179957,DB00273,Topiramate
,20376593,Serum half-life,"Serum half-life, which has not been studied after overdose, was 16 h.",Clinical effects and toxicokinetic evaluation following massive topiramate ingestion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20376593/),h,16,179958,DB00273,Topiramate
,20015615,ED(50),Riluzole (1-4mg/kg) administered intraperitoneally before pilocarpine dose-dependently protected rats against seizures with the anticonvulsant ED(50) value (50% effective anticonvulsant dose) of 1.8 (1.3-2.6)mg/kg.,Evidences for pharmacokinetic interaction of riluzole and topiramate with pilocarpine in pilocarpine-induced seizures in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015615/),[mg] / [kg],1.8,180133,DB00273,Topiramate
,20015615,50% effective anticonvulsant dose,Riluzole (1-4mg/kg) administered intraperitoneally before pilocarpine dose-dependently protected rats against seizures with the anticonvulsant ED(50) value (50% effective anticonvulsant dose) of 1.8 (1.3-2.6)mg/kg.,Evidences for pharmacokinetic interaction of riluzole and topiramate with pilocarpine in pilocarpine-induced seizures in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015615/),[mg] / [kg],1.8,180134,DB00273,Topiramate
,20015615,CD(50),"Topiramate significantly enhanced convulsive action of pilocarpine, lowering the convulsant CD(50) value (50% effective convulsant dose) of pilocarpine from 350.8 (329.2-373.8) to 246.4 (218.6-278.2)mg/kg.",Evidences for pharmacokinetic interaction of riluzole and topiramate with pilocarpine in pilocarpine-induced seizures in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015615/),[mg] / [kg],350.8,180135,DB00273,Topiramate
,20015615,CD(50),"Topiramate significantly enhanced convulsive action of pilocarpine, lowering the convulsant CD(50) value (50% effective convulsant dose) of pilocarpine from 350.8 (329.2-373.8) to 246.4 (218.6-278.2)mg/kg.",Evidences for pharmacokinetic interaction of riluzole and topiramate with pilocarpine in pilocarpine-induced seizures in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015615/),[mg] / [kg],246.4,180136,DB00273,Topiramate
,20015615,50% effective convulsant dose,"Topiramate significantly enhanced convulsive action of pilocarpine, lowering the convulsant CD(50) value (50% effective convulsant dose) of pilocarpine from 350.8 (329.2-373.8) to 246.4 (218.6-278.2)mg/kg.",Evidences for pharmacokinetic interaction of riluzole and topiramate with pilocarpine in pilocarpine-induced seizures in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015615/),[mg] / [kg],350.8,180137,DB00273,Topiramate
,20015615,50% effective convulsant dose,"Topiramate significantly enhanced convulsive action of pilocarpine, lowering the convulsant CD(50) value (50% effective convulsant dose) of pilocarpine from 350.8 (329.2-373.8) to 246.4 (218.6-278.2)mg/kg.",Evidences for pharmacokinetic interaction of riluzole and topiramate with pilocarpine in pilocarpine-induced seizures in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015615/),[mg] / [kg],246.4,180138,DB00273,Topiramate
,21256717,CL/F,"Mean population estimates (% CV interindividual variability) were 0.608/1.15 L/h (13%) for CL/F without/with EIAEDs, 28.6L (0.2%) for Vd/F and 1.4h(-1) (124%) for the absorption rate constant.",Topiramate pharmacokinetics in infants and young children: contribution of population analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256717/),[l] / [h],0.608,182679,DB00273,Topiramate
,21256717,Vd/F,"Mean population estimates (% CV interindividual variability) were 0.608/1.15 L/h (13%) for CL/F without/with EIAEDs, 28.6L (0.2%) for Vd/F and 1.4h(-1) (124%) for the absorption rate constant.",Topiramate pharmacokinetics in infants and young children: contribution of population analysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256717/),l,28.6,182680,DB00273,Topiramate
,21256717,absorption rate constant,"Mean population estimates (% CV interindividual variability) were 0.608/1.15 L/h (13%) for CL/F without/with EIAEDs, 28.6L (0.2%) for Vd/F and 1.4h(-1) (124%) for the absorption rate constant.",Topiramate pharmacokinetics in infants and young children: contribution of population analysis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256717/),1/[h],1.4,182681,DB00273,Topiramate
,25668796,flow rate,"Analyses were performed on a liquid chromatography system employing a Kromasil 60-5CN column (2.1 mm × 100 mm, 5 μm) and an isocratic elution with mixed solution of acetonitrile-20mM ammonium formate containing 0.3% formic acid (40:60, v/v), at a flow rate of 0.35 mL/min.",Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25668796/),[ml] / [min],0.35,182760,DB00273,Topiramate
,25668796,m/z,"The determination was carried out on an API 4000 triple-quadrupole mass spectrometer operated in multiple reaction monitoring (MRM) mode using the following transitions monitored simultaneously: positive m/z 150.0/91.0 for phentermine, m/z 452.1/344.3 for doxazosin, and negative m/z 338.3/77.9 for topiramate, m/z 355.0/41.9 for pioglitazone.",Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25668796/),,452.1,182761,DB00273,Topiramate
,25668796,m/z,"The determination was carried out on an API 4000 triple-quadrupole mass spectrometer operated in multiple reaction monitoring (MRM) mode using the following transitions monitored simultaneously: positive m/z 150.0/91.0 for phentermine, m/z 452.1/344.3 for doxazosin, and negative m/z 338.3/77.9 for topiramate, m/z 355.0/41.9 for pioglitazone.",Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25668796/),,344.3,182762,DB00273,Topiramate
,25668796,m/z,"The determination was carried out on an API 4000 triple-quadrupole mass spectrometer operated in multiple reaction monitoring (MRM) mode using the following transitions monitored simultaneously: positive m/z 150.0/91.0 for phentermine, m/z 452.1/344.3 for doxazosin, and negative m/z 338.3/77.9 for topiramate, m/z 355.0/41.9 for pioglitazone.",Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25668796/),,338.3,182763,DB00273,Topiramate
,25668796,m/z,"The determination was carried out on an API 4000 triple-quadrupole mass spectrometer operated in multiple reaction monitoring (MRM) mode using the following transitions monitored simultaneously: positive m/z 150.0/91.0 for phentermine, m/z 452.1/344.3 for doxazosin, and negative m/z 338.3/77.9 for topiramate, m/z 355.0/41.9 for pioglitazone.",Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25668796/),,77.9,182764,DB00273,Topiramate
,25668796,m/z,"The determination was carried out on an API 4000 triple-quadrupole mass spectrometer operated in multiple reaction monitoring (MRM) mode using the following transitions monitored simultaneously: positive m/z 150.0/91.0 for phentermine, m/z 452.1/344.3 for doxazosin, and negative m/z 338.3/77.9 for topiramate, m/z 355.0/41.9 for pioglitazone.",Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25668796/),,355.0,182765,DB00273,Topiramate
,25668796,m/z,"The determination was carried out on an API 4000 triple-quadrupole mass spectrometer operated in multiple reaction monitoring (MRM) mode using the following transitions monitored simultaneously: positive m/z 150.0/91.0 for phentermine, m/z 452.1/344.3 for doxazosin, and negative m/z 338.3/77.9 for topiramate, m/z 355.0/41.9 for pioglitazone.",Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25668796/),,41.9,182766,DB00273,Topiramate
,12837560,AUC/D,The average AUC/D was 0.72+/-0.18 h/l for the rectal dose and 0.76+/-0.20 h/l for the oral dose.,Relative bioavailability of topiramate administered rectally. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12837560/),[h] / [l],0.72,185710,DB00273,Topiramate
,12837560,AUC/D,The average AUC/D was 0.72+/-0.18 h/l for the rectal dose and 0.76+/-0.20 h/l for the oral dose.,Relative bioavailability of topiramate administered rectally. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12837560/),[h] / [l],0.76,185711,DB00273,Topiramate
,12837560,relative bioavailability,The relative bioavailability (n=10) for TPM administered rectally was 0.95+/-0.17 with a range of 0.68-1.2.,Relative bioavailability of topiramate administered rectally. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12837560/),,0.95,185712,DB00273,Topiramate
,16026556,CL/F,"Mean TPM CL/F and CL(r) were higher in the CBZ group than in controls (2.1 vs. 1.2 L/h and 1.1 vs. 0.6L/h, respectively; p < 0.05).",A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026556/),[l] / [h],2.1,186996,DB00273,Topiramate
,16026556,CL/F,"Mean TPM CL/F and CL(r) were higher in the CBZ group than in controls (2.1 vs. 1.2 L/h and 1.1 vs. 0.6L/h, respectively; p < 0.05).",A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026556/),[l] / [h],1.2,186997,DB00273,Topiramate
,16026556,CL(r),"Mean TPM CL/F and CL(r) were higher in the CBZ group than in controls (2.1 vs. 1.2 L/h and 1.1 vs. 0.6L/h, respectively; p < 0.05).",A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026556/),[l] / [h],1.1,186998,DB00273,Topiramate
,16026556,CL(r),"Mean TPM CL/F and CL(r) were higher in the CBZ group than in controls (2.1 vs. 1.2 L/h and 1.1 vs. 0.6L/h, respectively; p < 0.05).",A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026556/),[l] / [h],0.6,186999,DB00273,Topiramate
>,12731458,bioavailability,"Results of these studies indicate that levetiracetam has a very favorable pharmacokinetic profile, characterized by excellent oral absorption and bioavailability (> 95%) and a mean elimination half-life in adults, children and the elderly of 7, 6 and 10.5 h, respectively.",The pharmacokinetic characteristics of levetiracetam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12731458/),%,95,192152,DB00273,Topiramate
,12731458,elimination half-life,"Results of these studies indicate that levetiracetam has a very favorable pharmacokinetic profile, characterized by excellent oral absorption and bioavailability (> 95%) and a mean elimination half-life in adults, children and the elderly of 7, 6 and 10.5 h, respectively.",The pharmacokinetic characteristics of levetiracetam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12731458/),h,7,192153,DB00273,Topiramate
,12731458,elimination half-life,"Results of these studies indicate that levetiracetam has a very favorable pharmacokinetic profile, characterized by excellent oral absorption and bioavailability (> 95%) and a mean elimination half-life in adults, children and the elderly of 7, 6 and 10.5 h, respectively.",The pharmacokinetic characteristics of levetiracetam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12731458/),h,6,192154,DB00273,Topiramate
,12731458,elimination half-life,"Results of these studies indicate that levetiracetam has a very favorable pharmacokinetic profile, characterized by excellent oral absorption and bioavailability (> 95%) and a mean elimination half-life in adults, children and the elderly of 7, 6 and 10.5 h, respectively.",The pharmacokinetic characteristics of levetiracetam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12731458/),h,10.5,192155,DB00273,Topiramate
,28737428,LOD,"Linear behavior was observed in the range of 0.1-3 μg/ml and 0.01-0.5 μg/ml for the AEDs and SUL, respectively, with LOD of 33, 46 and 4 ng/ml and LOQ of 86, 93 and 9 ng/ml for ZON, TOP and SUL, respectively.","Chromatographic determination of zonisamide, topiramate and sulpiride in plasma by a fluorescent 'turn-on' chemosensor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28737428/),[ng] / [ml],33,196011,DB00273,Topiramate
,28737428,LOD,"Linear behavior was observed in the range of 0.1-3 μg/ml and 0.01-0.5 μg/ml for the AEDs and SUL, respectively, with LOD of 33, 46 and 4 ng/ml and LOQ of 86, 93 and 9 ng/ml for ZON, TOP and SUL, respectively.","Chromatographic determination of zonisamide, topiramate and sulpiride in plasma by a fluorescent 'turn-on' chemosensor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28737428/),[ng] / [ml],46,196012,DB00273,Topiramate
,28737428,LOD,"Linear behavior was observed in the range of 0.1-3 μg/ml and 0.01-0.5 μg/ml for the AEDs and SUL, respectively, with LOD of 33, 46 and 4 ng/ml and LOQ of 86, 93 and 9 ng/ml for ZON, TOP and SUL, respectively.","Chromatographic determination of zonisamide, topiramate and sulpiride in plasma by a fluorescent 'turn-on' chemosensor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28737428/),[ng] / [ml],4,196013,DB00273,Topiramate
,28737428,LOQ,"Linear behavior was observed in the range of 0.1-3 μg/ml and 0.01-0.5 μg/ml for the AEDs and SUL, respectively, with LOD of 33, 46 and 4 ng/ml and LOQ of 86, 93 and 9 ng/ml for ZON, TOP and SUL, respectively.","Chromatographic determination of zonisamide, topiramate and sulpiride in plasma by a fluorescent 'turn-on' chemosensor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28737428/),[ng] / [ml],86,196014,DB00273,Topiramate
,28737428,LOQ,"Linear behavior was observed in the range of 0.1-3 μg/ml and 0.01-0.5 μg/ml for the AEDs and SUL, respectively, with LOD of 33, 46 and 4 ng/ml and LOQ of 86, 93 and 9 ng/ml for ZON, TOP and SUL, respectively.","Chromatographic determination of zonisamide, topiramate and sulpiride in plasma by a fluorescent 'turn-on' chemosensor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28737428/),[ng] / [ml],93,196015,DB00273,Topiramate
,28737428,LOQ,"Linear behavior was observed in the range of 0.1-3 μg/ml and 0.01-0.5 μg/ml for the AEDs and SUL, respectively, with LOD of 33, 46 and 4 ng/ml and LOQ of 86, 93 and 9 ng/ml for ZON, TOP and SUL, respectively.","Chromatographic determination of zonisamide, topiramate and sulpiride in plasma by a fluorescent 'turn-on' chemosensor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28737428/),[ng] / [ml],9,196016,DB00273,Topiramate
,7720530,peak plasma concentration (Cmax),"Male and female beagle dogs showed rapid absorption following oral administration of single oral gavage (40 mg/kg) and single or multiple (15 days) oral capsule (10, 40, and 150 mg/kg) doses of the novel anticonvulsant drug, topiramate, with the peak plasma concentration (Cmax) occurring between 0.6 and 3.8 hr.",Pharmacokinetics and bioavailability of topiramate in the beagle dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7720530/),h,0.6 and 3.8,201060,DB00273,Topiramate
,7720530,absolute bioavailability,"The absolute bioavailability of an oral dose of topiramate was estimated to be in the range of 27-59%, depending on the formulation.",Pharmacokinetics and bioavailability of topiramate in the beagle dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7720530/),%,27-59,201061,DB00273,Topiramate
,7720530,Cmax,"The mean topiramate Cmax values increased in a dose-proportional manner for both single (9.2-137.7 micrograms/ml) and multiple (10.3-145.2 micrograms/ml) oral capsule administrations, whereas the corresponding area under the plasma concentration vs. time curve (AUC) values increased in a dose-related but nonproportional manner for both single (51-1131 micrograms.hr/ml) and multiple (54-858 micrograms.hr/ml) doses.",Pharmacokinetics and bioavailability of topiramate in the beagle dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7720530/),,9.2-137.7,201062,DB00273,Topiramate
,7720530,area under the plasma concentration vs. time curve (AUC),"The mean topiramate Cmax values increased in a dose-proportional manner for both single (9.2-137.7 micrograms/ml) and multiple (10.3-145.2 micrograms/ml) oral capsule administrations, whereas the corresponding area under the plasma concentration vs. time curve (AUC) values increased in a dose-related but nonproportional manner for both single (51-1131 micrograms.hr/ml) and multiple (54-858 micrograms.hr/ml) doses.",Pharmacokinetics and bioavailability of topiramate in the beagle dog. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7720530/),[h·μg] / [ml],51-1131,201063,DB00273,Topiramate
,7720530,area under the plasma concentration vs. time curve (AUC),"The mean topiramate Cmax values increased in a dose-proportional manner for both single (9.2-137.7 micrograms/ml) and multiple (10.3-145.2 micrograms/ml) oral capsule administrations, whereas the corresponding area under the plasma concentration vs. time curve (AUC) values increased in a dose-related but nonproportional manner for both single (51-1131 micrograms.hr/ml) and multiple (54-858 micrograms.hr/ml) doses.",Pharmacokinetics and bioavailability of topiramate in the beagle dog. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7720530/),[h·μg] / [ml],54-858,201064,DB00273,Topiramate
,7720530,oral plasma clearance,"Over the 10-150 mg/kg dosing range, oral plasma clearance and terminal half-life values were found to be 2.4-3.6 ml/min/kg and 2.6-3.7 hr following a single oral administration, and 3.0-4.2 ml/min/kg and 2.0-3.8 hr after multiple doses.",Pharmacokinetics and bioavailability of topiramate in the beagle dog. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7720530/),[ml] / [kg·min],2.4-3.6,201065,DB00273,Topiramate
,7720530,oral plasma clearance,"Over the 10-150 mg/kg dosing range, oral plasma clearance and terminal half-life values were found to be 2.4-3.6 ml/min/kg and 2.6-3.7 hr following a single oral administration, and 3.0-4.2 ml/min/kg and 2.0-3.8 hr after multiple doses.",Pharmacokinetics and bioavailability of topiramate in the beagle dog. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7720530/),[ml] / [kg·min],3.0-4.2,201066,DB00273,Topiramate
,7720530,terminal half-life,"Over the 10-150 mg/kg dosing range, oral plasma clearance and terminal half-life values were found to be 2.4-3.6 ml/min/kg and 2.6-3.7 hr following a single oral administration, and 3.0-4.2 ml/min/kg and 2.0-3.8 hr after multiple doses.",Pharmacokinetics and bioavailability of topiramate in the beagle dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7720530/),h,2.6-3.7,201067,DB00273,Topiramate
,7720530,terminal half-life,"Over the 10-150 mg/kg dosing range, oral plasma clearance and terminal half-life values were found to be 2.4-3.6 ml/min/kg and 2.6-3.7 hr following a single oral administration, and 3.0-4.2 ml/min/kg and 2.0-3.8 hr after multiple doses.",Pharmacokinetics and bioavailability of topiramate in the beagle dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7720530/),h,2.0-3.8,201068,DB00273,Topiramate
,20420791,AUC(0-inf),"Based on plasma concentration-time profiles we obtained the following pharmacokinetic parameters: AUC(0-inf) 63,418.31 +/- 22,141.69 and 67,094.70 +/- 22,487.2 ngh/ml; AUC0-24: 30,421.02 +/- 9,964.0 and 30,489.35 +/- 9,407.17, ng x h/ml; tmax: 2.77 +/- 1.76 and 1.95 +/- 1.89 h; C(max): 2,143.33 +/- 724.26 and 2,262.51 +/- 751.12 ng/ml, for A (Toprel) and B (Topamax), respectively.",Relative bioavailability study with two oral formulations of topiramate using a validated UPLC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20420791/),[ngh] / [ml],"63,418.31",201955,DB00273,Topiramate
,20420791,AUC(0-inf),"Based on plasma concentration-time profiles we obtained the following pharmacokinetic parameters: AUC(0-inf) 63,418.31 +/- 22,141.69 and 67,094.70 +/- 22,487.2 ngh/ml; AUC0-24: 30,421.02 +/- 9,964.0 and 30,489.35 +/- 9,407.17, ng x h/ml; tmax: 2.77 +/- 1.76 and 1.95 +/- 1.89 h; C(max): 2,143.33 +/- 724.26 and 2,262.51 +/- 751.12 ng/ml, for A (Toprel) and B (Topamax), respectively.",Relative bioavailability study with two oral formulations of topiramate using a validated UPLC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20420791/),[ngh] / [ml],"67,094.70",201956,DB00273,Topiramate
,20420791,AUC0-24,"Based on plasma concentration-time profiles we obtained the following pharmacokinetic parameters: AUC(0-inf) 63,418.31 +/- 22,141.69 and 67,094.70 +/- 22,487.2 ngh/ml; AUC0-24: 30,421.02 +/- 9,964.0 and 30,489.35 +/- 9,407.17, ng x h/ml; tmax: 2.77 +/- 1.76 and 1.95 +/- 1.89 h; C(max): 2,143.33 +/- 724.26 and 2,262.51 +/- 751.12 ng/ml, for A (Toprel) and B (Topamax), respectively.",Relative bioavailability study with two oral formulations of topiramate using a validated UPLC-MS/MS method. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20420791/),[h·ng] / [ml],"30,421.02",201957,DB00273,Topiramate
,20420791,AUC0-24,"Based on plasma concentration-time profiles we obtained the following pharmacokinetic parameters: AUC(0-inf) 63,418.31 +/- 22,141.69 and 67,094.70 +/- 22,487.2 ngh/ml; AUC0-24: 30,421.02 +/- 9,964.0 and 30,489.35 +/- 9,407.17, ng x h/ml; tmax: 2.77 +/- 1.76 and 1.95 +/- 1.89 h; C(max): 2,143.33 +/- 724.26 and 2,262.51 +/- 751.12 ng/ml, for A (Toprel) and B (Topamax), respectively.",Relative bioavailability study with two oral formulations of topiramate using a validated UPLC-MS/MS method. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20420791/),[h·ng] / [ml],"30,489.35",201958,DB00273,Topiramate
,20420791,tmax,"Based on plasma concentration-time profiles we obtained the following pharmacokinetic parameters: AUC(0-inf) 63,418.31 +/- 22,141.69 and 67,094.70 +/- 22,487.2 ngh/ml; AUC0-24: 30,421.02 +/- 9,964.0 and 30,489.35 +/- 9,407.17, ng x h/ml; tmax: 2.77 +/- 1.76 and 1.95 +/- 1.89 h; C(max): 2,143.33 +/- 724.26 and 2,262.51 +/- 751.12 ng/ml, for A (Toprel) and B (Topamax), respectively.",Relative bioavailability study with two oral formulations of topiramate using a validated UPLC-MS/MS method. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20420791/),h,2.77,201959,DB00273,Topiramate
,20420791,tmax,"Based on plasma concentration-time profiles we obtained the following pharmacokinetic parameters: AUC(0-inf) 63,418.31 +/- 22,141.69 and 67,094.70 +/- 22,487.2 ngh/ml; AUC0-24: 30,421.02 +/- 9,964.0 and 30,489.35 +/- 9,407.17, ng x h/ml; tmax: 2.77 +/- 1.76 and 1.95 +/- 1.89 h; C(max): 2,143.33 +/- 724.26 and 2,262.51 +/- 751.12 ng/ml, for A (Toprel) and B (Topamax), respectively.",Relative bioavailability study with two oral formulations of topiramate using a validated UPLC-MS/MS method. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20420791/),h,1.95,201960,DB00273,Topiramate
,20420791,C(max),"Based on plasma concentration-time profiles we obtained the following pharmacokinetic parameters: AUC(0-inf) 63,418.31 +/- 22,141.69 and 67,094.70 +/- 22,487.2 ngh/ml; AUC0-24: 30,421.02 +/- 9,964.0 and 30,489.35 +/- 9,407.17, ng x h/ml; tmax: 2.77 +/- 1.76 and 1.95 +/- 1.89 h; C(max): 2,143.33 +/- 724.26 and 2,262.51 +/- 751.12 ng/ml, for A (Toprel) and B (Topamax), respectively.",Relative bioavailability study with two oral formulations of topiramate using a validated UPLC-MS/MS method. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20420791/),[ng] / [ml],"2,143.33",201961,DB00273,Topiramate
,20420791,C(max),"Based on plasma concentration-time profiles we obtained the following pharmacokinetic parameters: AUC(0-inf) 63,418.31 +/- 22,141.69 and 67,094.70 +/- 22,487.2 ngh/ml; AUC0-24: 30,421.02 +/- 9,964.0 and 30,489.35 +/- 9,407.17, ng x h/ml; tmax: 2.77 +/- 1.76 and 1.95 +/- 1.89 h; C(max): 2,143.33 +/- 724.26 and 2,262.51 +/- 751.12 ng/ml, for A (Toprel) and B (Topamax), respectively.",Relative bioavailability study with two oral formulations of topiramate using a validated UPLC-MS/MS method. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20420791/),[ng] / [ml],"2,262.51",201962,DB00273,Topiramate
,19764603,Serum protein binding,"Serum protein binding is approximately 15%, and biologic half-life in healthy volunteers is considered to range from 20 to 30 hours.",[Current clinical evidence on topiramate pharmacokinetics]. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19764603/),%,15,205724,DB00273,Topiramate
,19764603,biologic half-life,"Serum protein binding is approximately 15%, and biologic half-life in healthy volunteers is considered to range from 20 to 30 hours.",[Current clinical evidence on topiramate pharmacokinetics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19764603/),h,20 to 30,205725,DB00273,Topiramate
,19764603,distribution volume rates,"Mean expected distribution volume rates from 0.55-0.8 l/kg, and accordingly, the drug shows a low and saturable binding capacity toward erythrocytes.",[Current clinical evidence on topiramate pharmacokinetics]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19764603/),[l] / [kg],0.55-0.8,205726,DB00273,Topiramate
,17598694,elimination half-life,Mean +/- standard deviation elimination half-life for the reference formulation was 84.18 +/- 14.61h whereas for the test formulation it was 80.82 +/- 11.50h.,"Truncated AUCs in the assessment of the bioequivalence of topiramate, a long half-life drug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17598694/),h,84.18,207009,DB00273,Topiramate
,17598694,elimination half-life,Mean +/- standard deviation elimination half-life for the reference formulation was 84.18 +/- 14.61h whereas for the test formulation it was 80.82 +/- 11.50h.,"Truncated AUCs in the assessment of the bioequivalence of topiramate, a long half-life drug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17598694/),h,80.82,207010,DB00273,Topiramate
,15730535,oral clearance (CL/F),Mean TPM oral clearance (CL/F) increased from 1.2 L/h (control) to 2.2 L/h after CBZ treatment.,Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15730535/),[l] / [h],1.2,212712,DB00273,Topiramate
,15730535,oral clearance (CL/F),Mean TPM oral clearance (CL/F) increased from 1.2 L/h (control) to 2.2 L/h after CBZ treatment.,Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15730535/),[l] / [h],2.2,212713,DB00273,Topiramate
,15730535,half-life,Mean TPM half-life decreased from 29 h to 19 h.,Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15730535/),h,29,212714,DB00273,Topiramate
,15730535,half-life,Mean TPM half-life decreased from 29 h to 19 h.,Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15730535/),h,19,212715,DB00273,Topiramate
,15730535,recovery,"Corresponding recovery values for 10-hydroxy-TPM (10-OH-TPM) were 1.2% and 1.8%, respectively.",Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15730535/),%,1.2,212716,DB00273,Topiramate
,15730535,recovery,"Corresponding recovery values for 10-hydroxy-TPM (10-OH-TPM) were 1.2% and 1.8%, respectively.",Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15730535/),%,1.8,212717,DB00273,Topiramate
,15730535,AUC,"The control AUC(metabolite)/AUC(drug) ratio for 2,3-diol-TPM and 10-OH-TPM were 1.5% and 0.6%, and they increased by threefold and twofold, respectively, after CBZ treatment.",Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15730535/),,0,212718,DB00273,Topiramate
,23254278,steady-state maximum,Mean predicted steady-state maximum and average concentrations following 30 mg/kg TPM were 31.3 and 16.8 μg/ml in Long Evans and 39.9 and 24.4 μg/ml in Sprague-Dawley pups.,Plasma topiramate concentrations resulting from doses associated with neuroprotection against white matter injury and stroke in two strains of rat pups. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23254278/),[μg] / [ml],31.3,214522,DB00273,Topiramate
,23254278,steady-state maximum,Mean predicted steady-state maximum and average concentrations following 30 mg/kg TPM were 31.3 and 16.8 μg/ml in Long Evans and 39.9 and 24.4 μg/ml in Sprague-Dawley pups.,Plasma topiramate concentrations resulting from doses associated with neuroprotection against white matter injury and stroke in two strains of rat pups. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23254278/),[μg] / [ml],16.8,214523,DB00273,Topiramate
,23254278,steady-state maximum,Mean predicted steady-state maximum and average concentrations following 30 mg/kg TPM were 31.3 and 16.8 μg/ml in Long Evans and 39.9 and 24.4 μg/ml in Sprague-Dawley pups.,Plasma topiramate concentrations resulting from doses associated with neuroprotection against white matter injury and stroke in two strains of rat pups. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23254278/),[μg] / [ml],39.9,214524,DB00273,Topiramate
,23254278,concentrations,Mean predicted steady-state maximum and average concentrations following 30 mg/kg TPM were 31.3 and 16.8 μg/ml in Long Evans and 39.9 and 24.4 μg/ml in Sprague-Dawley pups.,Plasma topiramate concentrations resulting from doses associated with neuroprotection against white matter injury and stroke in two strains of rat pups. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23254278/),[μg] / [ml],16.8,214525,DB00273,Topiramate
,23254278,concentrations,Mean predicted steady-state maximum and average concentrations following 30 mg/kg TPM were 31.3 and 16.8 μg/ml in Long Evans and 39.9 and 24.4 μg/ml in Sprague-Dawley pups.,Plasma topiramate concentrations resulting from doses associated with neuroprotection against white matter injury and stroke in two strains of rat pups. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23254278/),[μg] / [ml],39.9,214526,DB00273,Topiramate
,23254278,concentrations,Mean predicted steady-state maximum and average concentrations following 30 mg/kg TPM were 31.3 and 16.8 μg/ml in Long Evans and 39.9 and 24.4 μg/ml in Sprague-Dawley pups.,Plasma topiramate concentrations resulting from doses associated with neuroprotection against white matter injury and stroke in two strains of rat pups. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23254278/),[μg] / [ml],24.4,214527,DB00273,Topiramate
,23254278,steady-state maximum,Mean predicted steady-state maximum and average concentrations following 50 mg/kg TPM were 52.1 and 28.1 μg/ml in Long Evans and 66.5 and 40.6 μg/ml in Sprague-Dawley pups.,Plasma topiramate concentrations resulting from doses associated with neuroprotection against white matter injury and stroke in two strains of rat pups. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23254278/),[μg] / [ml],52.1,214528,DB00273,Topiramate
,23254278,steady-state maximum,Mean predicted steady-state maximum and average concentrations following 50 mg/kg TPM were 52.1 and 28.1 μg/ml in Long Evans and 66.5 and 40.6 μg/ml in Sprague-Dawley pups.,Plasma topiramate concentrations resulting from doses associated with neuroprotection against white matter injury and stroke in two strains of rat pups. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23254278/),[μg] / [ml],28.1,214529,DB00273,Topiramate
,23254278,steady-state maximum,Mean predicted steady-state maximum and average concentrations following 50 mg/kg TPM were 52.1 and 28.1 μg/ml in Long Evans and 66.5 and 40.6 μg/ml in Sprague-Dawley pups.,Plasma topiramate concentrations resulting from doses associated with neuroprotection against white matter injury and stroke in two strains of rat pups. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23254278/),[μg] / [ml],66.5,214530,DB00273,Topiramate
,23254278,concentrations,Mean predicted steady-state maximum and average concentrations following 50 mg/kg TPM were 52.1 and 28.1 μg/ml in Long Evans and 66.5 and 40.6 μg/ml in Sprague-Dawley pups.,Plasma topiramate concentrations resulting from doses associated with neuroprotection against white matter injury and stroke in two strains of rat pups. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23254278/),[μg] / [ml],28.1,214531,DB00273,Topiramate
,23254278,concentrations,Mean predicted steady-state maximum and average concentrations following 50 mg/kg TPM were 52.1 and 28.1 μg/ml in Long Evans and 66.5 and 40.6 μg/ml in Sprague-Dawley pups.,Plasma topiramate concentrations resulting from doses associated with neuroprotection against white matter injury and stroke in two strains of rat pups. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23254278/),[μg] / [ml],66.5,214532,DB00273,Topiramate
,23254278,concentrations,Mean predicted steady-state maximum and average concentrations following 50 mg/kg TPM were 52.1 and 28.1 μg/ml in Long Evans and 66.5 and 40.6 μg/ml in Sprague-Dawley pups.,Plasma topiramate concentrations resulting from doses associated with neuroprotection against white matter injury and stroke in two strains of rat pups. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23254278/),[μg] / [ml],40.6,214533,DB00273,Topiramate
,23254278,apparent clearance (CL/F),"The apparent clearance (CL/F) and apparent volume of distribution (V/F) were 0.0470 ml/min and 22.2 ml, respectively, for Long Evans and 0.0325 ml/min and 19.7 ml, respectively, for Sprague-Dawley pups.",Plasma topiramate concentrations resulting from doses associated with neuroprotection against white matter injury and stroke in two strains of rat pups. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23254278/),[ml] / [min],0.0470,214534,DB00273,Topiramate
,23254278,apparent clearance (CL/F),"The apparent clearance (CL/F) and apparent volume of distribution (V/F) were 0.0470 ml/min and 22.2 ml, respectively, for Long Evans and 0.0325 ml/min and 19.7 ml, respectively, for Sprague-Dawley pups.",Plasma topiramate concentrations resulting from doses associated with neuroprotection against white matter injury and stroke in two strains of rat pups. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23254278/),[ml] / [min],0.0325,214535,DB00273,Topiramate
,23254278,apparent volume of distribution (V/F),"The apparent clearance (CL/F) and apparent volume of distribution (V/F) were 0.0470 ml/min and 22.2 ml, respectively, for Long Evans and 0.0325 ml/min and 19.7 ml, respectively, for Sprague-Dawley pups.",Plasma topiramate concentrations resulting from doses associated with neuroprotection against white matter injury and stroke in two strains of rat pups. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23254278/),ml,22.2,214536,DB00273,Topiramate
,23254278,apparent volume of distribution (V/F),"The apparent clearance (CL/F) and apparent volume of distribution (V/F) were 0.0470 ml/min and 22.2 ml, respectively, for Long Evans and 0.0325 ml/min and 19.7 ml, respectively, for Sprague-Dawley pups.",Plasma topiramate concentrations resulting from doses associated with neuroprotection against white matter injury and stroke in two strains of rat pups. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23254278/),ml,19.7,214537,DB00273,Topiramate
,28230619,apparent volume of distribution,"Based on a one-compartment model with first order absorption and elimination, the apparent volume of distribution was 105 L/70 kg, and the apparent clearance was allometrically related to the body weight as 2.25 L·h·70 kg without carbamazepine or phenytoin.",Population Pharmacokinetics of Topiramate in Japanese Pediatric and Adult Patients With Epilepsy Using Routinely Monitored Data. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28230619/),[l] / [70·kg],105,214960,DB00273,Topiramate
,28230619,apparent clearance,Combination treatment with carbamazepine or phenytoin increased the apparent clearance to 3.51 L·h·70 kg.,Population Pharmacokinetics of Topiramate in Japanese Pediatric and Adult Patients With Epilepsy Using Routinely Monitored Data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28230619/),70·h·kg·l,3.51,214961,DB00273,Topiramate
,15715969,blood-to-plasma ratio,"At low therapeutic concentrations, the blood-to-plasma ratio for TPM decreased from 8 to 2 as its concentration increased, indicating a substantial and saturable binding of TPM to erythrocytes.",Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15715969/),,8,216680,DB00273,Topiramate
,15715969,blood-to-plasma ratio,"At low therapeutic concentrations, the blood-to-plasma ratio for TPM decreased from 8 to 2 as its concentration increased, indicating a substantial and saturable binding of TPM to erythrocytes.",Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15715969/),,2,216681,DB00273,Topiramate
,15715969,Kd,"This analysis indicated the existence of two binding sites with Kd values of 0.54 and 140 microM, and Bmax values of 22 and 124 micromol/L of erythrocyte volume, respectively.",Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15715969/),μM,0.54,216682,DB00273,Topiramate
,15715969,Kd,"This analysis indicated the existence of two binding sites with Kd values of 0.54 and 140 microM, and Bmax values of 22 and 124 micromol/L of erythrocyte volume, respectively.",Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15715969/),μM,140,216683,DB00273,Topiramate
,15715969,Bmax,"This analysis indicated the existence of two binding sites with Kd values of 0.54 and 140 microM, and Bmax values of 22 and 124 micromol/L of erythrocyte volume, respectively.",Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15715969/),[μM] / [l],22,216684,DB00273,Topiramate
,15715969,Bmax,"This analysis indicated the existence of two binding sites with Kd values of 0.54 and 140 microM, and Bmax values of 22 and 124 micromol/L of erythrocyte volume, respectively.",Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15715969/),[μM] / [l],124,216685,DB00273,Topiramate
,15715969,Bmax,These Bmax values are similar to literature values for the molar concentration of human CA-II (14-25 micromol/L) and CA-I (115-125 micromol/L).,Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15715969/),,14-25,216686,DB00273,Topiramate
,15715969,Bmax,These Bmax values are similar to literature values for the molar concentration of human CA-II (14-25 micromol/L) and CA-I (115-125 micromol/L).,Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15715969/),μ,115-125,216687,DB00273,Topiramate
,15715969,inhibition constant (Ki),"TPM inhibition constant (Ki) values for the inhibition of purified human CA obtained using assays based on CO2 hydration or 4-nitrophenylacetate hydrolysis were 0.62 and 0.49 microM for CA-II, and 91 and 93 microM for CA-I.",Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15715969/),μM,0.62,216688,DB00273,Topiramate
,15715969,inhibition constant (Ki),"TPM inhibition constant (Ki) values for the inhibition of purified human CA obtained using assays based on CO2 hydration or 4-nitrophenylacetate hydrolysis were 0.62 and 0.49 microM for CA-II, and 91 and 93 microM for CA-I.",Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15715969/),μM,0.49,216689,DB00273,Topiramate
,15715969,inhibition constant (Ki),"TPM inhibition constant (Ki) values for the inhibition of purified human CA obtained using assays based on CO2 hydration or 4-nitrophenylacetate hydrolysis were 0.62 and 0.49 microM for CA-II, and 91 and 93 microM for CA-I.",Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15715969/),μM,91,216690,DB00273,Topiramate
,15715969,inhibition constant (Ki),"TPM inhibition constant (Ki) values for the inhibition of purified human CA obtained using assays based on CO2 hydration or 4-nitrophenylacetate hydrolysis were 0.62 and 0.49 microM for CA-II, and 91 and 93 microM for CA-I.",Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15715969/),μM,93,216691,DB00273,Topiramate
,21034737,ED(50),"In this study, chronic bupropion pretreatment intraperitoneally (i.p.) for 14 days in a dose of 5 mg/kg reduced the ED(50) (i.e. the dose protecting 50% of mice against electroconvulsions) of lamotrigine, topiramate, and felbamate from 4.58, 60.95, and 48.79 (antiepileptic+vehicle) to 3.01, 41.68, and 37.28 mg/kg (antiepileptic+bupropion), respectively, against maximal electroshock-induced seizures in mice.","Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034737/),[mg] / [kg],4.58,224633,DB00273,Topiramate
,21034737,ED(50),"In this study, chronic bupropion pretreatment intraperitoneally (i.p.) for 14 days in a dose of 5 mg/kg reduced the ED(50) (i.e. the dose protecting 50% of mice against electroconvulsions) of lamotrigine, topiramate, and felbamate from 4.58, 60.95, and 48.79 (antiepileptic+vehicle) to 3.01, 41.68, and 37.28 mg/kg (antiepileptic+bupropion), respectively, against maximal electroshock-induced seizures in mice.","Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034737/),[mg] / [kg],60.95,224634,DB00273,Topiramate
,21034737,ED(50),"In this study, chronic bupropion pretreatment intraperitoneally (i.p.) for 14 days in a dose of 5 mg/kg reduced the ED(50) (i.e. the dose protecting 50% of mice against electroconvulsions) of lamotrigine, topiramate, and felbamate from 4.58, 60.95, and 48.79 (antiepileptic+vehicle) to 3.01, 41.68, and 37.28 mg/kg (antiepileptic+bupropion), respectively, against maximal electroshock-induced seizures in mice.","Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034737/),[mg] / [kg],48.79,224635,DB00273,Topiramate
,21034737,ED(50),"In this study, chronic bupropion pretreatment intraperitoneally (i.p.) for 14 days in a dose of 5 mg/kg reduced the ED(50) (i.e. the dose protecting 50% of mice against electroconvulsions) of lamotrigine, topiramate, and felbamate from 4.58, 60.95, and 48.79 (antiepileptic+vehicle) to 3.01, 41.68, and 37.28 mg/kg (antiepileptic+bupropion), respectively, against maximal electroshock-induced seizures in mice.","Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034737/),[mg] / [kg],3.01,224636,DB00273,Topiramate
,21034737,ED(50),"In this study, chronic bupropion pretreatment intraperitoneally (i.p.) for 14 days in a dose of 5 mg/kg reduced the ED(50) (i.e. the dose protecting 50% of mice against electroconvulsions) of lamotrigine, topiramate, and felbamate from 4.58, 60.95, and 48.79 (antiepileptic+vehicle) to 3.01, 41.68, and 37.28 mg/kg (antiepileptic+bupropion), respectively, against maximal electroshock-induced seizures in mice.","Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034737/),[mg] / [kg],41.68,224637,DB00273,Topiramate
,21034737,ED(50),"In this study, chronic bupropion pretreatment intraperitoneally (i.p.) for 14 days in a dose of 5 mg/kg reduced the ED(50) (i.e. the dose protecting 50% of mice against electroconvulsions) of lamotrigine, topiramate, and felbamate from 4.58, 60.95, and 48.79 (antiepileptic+vehicle) to 3.01, 41.68, and 37.28 mg/kg (antiepileptic+bupropion), respectively, against maximal electroshock-induced seizures in mice.","Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034737/),[mg] / [kg],37.28,224638,DB00273,Topiramate
,15334626,clearance,"Plasma topiramate concentrations following an intravenous dose were best described by a bi-exponential equation, with a mean clearance of 39+/-18 ml/h/kg, and a terminal half-life of 14.3 (range 7.5-48.1) h.",The plasma pharmacokinetics and cerebral spinal fluid penetration of intravenous topiramate in newborn pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15334626/),[ml] / [h·kg],39,225733,DB00273,Topiramate
,15334626,terminal half-life,"Plasma topiramate concentrations following an intravenous dose were best described by a bi-exponential equation, with a mean clearance of 39+/-18 ml/h/kg, and a terminal half-life of 14.3 (range 7.5-48.1) h.",The plasma pharmacokinetics and cerebral spinal fluid penetration of intravenous topiramate in newborn pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15334626/),h,14.3,225734,DB00273,Topiramate
,15334626,concentration,"CSF topiramate concentration at 1 h was 12+/-1 micro M and 109+/-26 micro M at the 5 and 40 mg/kg doses, respectively.",The plasma pharmacokinetics and cerebral spinal fluid penetration of intravenous topiramate in newborn pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15334626/),μM,12,225735,DB00273,Topiramate
,15334626,concentration,"CSF topiramate concentration at 1 h was 12+/-1 micro M and 109+/-26 micro M at the 5 and 40 mg/kg doses, respectively.",The plasma pharmacokinetics and cerebral spinal fluid penetration of intravenous topiramate in newborn pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15334626/),μM,109,225736,DB00273,Topiramate
,34255318,total clearance,The population mean value of lamotrigine total clearance generated in the final model (with covariates) was 2.12 L/hr.,Population Pharmacokinetics Modeling of Lamotrigine in Jordanian Epileptic Patients Using Dried Blood Spot Sampling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34255318/),[l] / [h],2.12,226356,DB00273,Topiramate
,8827398,half-life,"When used as a monotherapy, topiramate is eliminated primarily in the urine in an unchanged form with a half-life of 20 to 30 hours; elimination is faster in patients receiving concurrent medication with enzyme-inducing anticonvulsants, in whom the extent of biotransformation becomes more prominent.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,20 to 30,232847,DB00273,Topiramate
,8827398,half-life,"It is rapidly absorbed, 50% bound to plasma proteins and is eliminated predominantly by biotransformation; zonisamide has a half-life of 50 to 70 hours in monotherapy patients, or 25 to 35 hours in patients comedicated with enzyme-inducing anticonvulsants.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,50 to 70,232848,DB00273,Topiramate
,8827398,half-life,"It is rapidly absorbed, 50% bound to plasma proteins and is eliminated predominantly by biotransformation; zonisamide has a half-life of 50 to 70 hours in monotherapy patients, or 25 to 35 hours in patients comedicated with enzyme-inducing anticonvulsants.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,25 to 35,232849,DB00273,Topiramate
,8827398,half-life,"It is highly (96%) bound to plasma proteins and it is eliminated primarily by cytochrome P450 3A-mediated oxidation, with a half-life of about 7 hours in healthy volunteers.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,7,232850,DB00273,Topiramate
,25380628,CL/F,Typical value of PB CL/F for final model was estimated at 0.314 l/h.,Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25380628/),[l] / [h],0.314,249519,DB00273,Topiramate
,26395889,EC50,"At the EC50 of 2.85 μg/mL, this topiramate plasma concentration value was estimated to be associated with a 25.5% reduction of SDMT score relative to baseline.",Pharmacokinetic-Pharmacodynamic Modeling of Intravenous and Oral Topiramate and Its Effect on the Symbol-Digit Modalities Test in Adult Healthy Volunteers. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26395889/),[μg] / [ml],2.85,252575,DB00273,Topiramate
,12915337,half-life,"Although its half-life is relatively short (6 to 8 hours), its duration of action is longer than anticipated from its pharmacokinetics in plasma, and a twice-daily dosing regimen is adequate to produce the desired response.",The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915337/),h,6 to 8,271378,DB00273,Topiramate
